Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.
暂无分享,去创建一个
L. Kuller | B. Psaty | M. Cushman | R. Tracy | E. Bovill | E. Cornell | E. Macy | B. Psaty | Mary Cushman | E. G. Bovill | B. Psaty | Elaine Cornell | L. H. Kuller | Russell P. Tracy
[1] P. Savage,et al. Association of Fibrinogen and Coagulation Factors Vll and VIII with Cardiovascular Risk Factors in the Elderly The Cardiovascular Health Study , 1996 .
[2] L. Kuller,et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. , 1995, Annals of epidemiology.
[3] M. Cushman,et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.
[4] J. Cooper,et al. The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.
[5] T. Ortel,et al. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. , 1994, Clinical chemistry.
[6] R. Rauramaa,et al. Apolipoprotein(a), Fibrinopeptide A and Carotid Atherosclerosis in Middle-Aged Men , 1994, Thrombosis and Haemostasis.
[7] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[8] M. Pirisi,et al. Fibrinogen Plasma Levels as a Marker of Thrombin Activation: New Insights on the Role of Fibrinogen as a Cardiovascular Risk Factor , 1994, Thrombosis and Haemostasis.
[9] G. Assmann,et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[10] V. Fuster,et al. Atherogenesis and inflammation. , 1993, European heart journal.
[11] J. Polak,et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.
[12] L. Fried,et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.
[13] E. Ernst,et al. Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.
[14] J. Philippé,et al. Coagulation system activation and increase of D‐dimer levels in peripheral arterial occlusive disease , 1993, American journal of hematology.
[15] P. Ridker,et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.
[16] A. Stead,et al. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. , 1993, Clinical Chemistry.
[17] M. Tennant,et al. Lipoprotein(a) and its role in occlusive vascular disease. , 1993, Annals of the Royal College of Surgeons of England.
[18] Tracy Rp,et al. Thrombosis and cardiovascular risk in the elderly. , 1992 .
[19] V. Fuster,et al. Thrombosis in Cardiovascular Disorders , 1992, Annals of Internal Medicine.
[20] L. Tavazzi,et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[21] S. Hifumi,et al. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[22] P. Savage,et al. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. , 1992, Annals of epidemiology.
[23] B. Psaty,et al. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. , 1992, The American journal of cardiology.
[24] K. Bauer,et al. Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease , 1992, Thrombosis and Haemostasis.
[25] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.
[26] B. Boneu,et al. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. , 1992, Nouvelle revue francaise d'hematologie.
[27] H. S. Klopfenstein,et al. Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. , 1992, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[28] B M Psaty,et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1991, Stroke.
[29] P C Elwood,et al. Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.
[30] W. Stüber,et al. Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.
[31] R. Kronmal,et al. The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.
[32] J. Badimón,et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. , 1990, Circulation.
[33] P. Hass,et al. A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). , 1990, Clinical chemistry.
[34] A. Gershlick. Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically? , 1990, Circulation.
[35] J. Owen. The Utility of Plasma Fibrinopeptide Assays , 1989, Thrombosis and Haemostasis.
[36] P. Rentrop,et al. Impaired Fibrinolytic Capacity and Tissue Plasminogen Activator Release in Patients with Restenosis after Percutaneous Transluminal Coronary Angioplasty (PTCA) , 1989, Thrombosis and Haemostasis.
[37] P. Fratino,et al. Fibrinopeptide A levels in patients with acute ischaemic heart disease. , 1989, Haemostasis.
[38] P. Mombaerts,et al. Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis , 1987, Thrombosis and Haemostasis.
[39] P. Vokonas,et al. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. , 1987, The Journal of clinical investigation.
[40] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[41] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[42] P. Théroux,et al. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. , 1987, Circulation.
[43] S. Thompson,et al. HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.
[44] A. Jaffe,et al. Fibrinopeptide A: a marker of acute coronary thrombosis. , 1985, Circulation.
[45] J. Soria,et al. Markers of Fibrinogen Derivatives Used in Clinical Investigation , 1985, Seminars in thrombosis and hemostasis.
[46] Daniel B. Mark,et al. Acute Coronary Care , 1985, Springer US.
[47] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[48] S. Frebelius,et al. Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. , 1980, Thrombosis research.
[49] J. Hirsh,et al. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. , 1978, Blood.
[50] R. Canfield,et al. Measurement of fibrinopeptide A in human blood. , 1974, The Journal of clinical investigation.
[51] E. Simonson,et al. The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.